Antineoplastic Agents: Immunotherapeutic Agents
IONCO1 “Oncotice bladder irrigation”12.5 mg/vial
適應症：原位性膀胱癌免疫治療。
Usual dose:
Adults: intravesical use
Induction therapy: Initiate one dose (one vial) instilled into the bladder (retain for 2 hours) between 7-14 days after biopsy or transurethral resection, qw × 6 weeks (may repeat cycle 1 time if tumor remission not achieved), followed by rest for 6 weeks.
Maintenance therapy: One dose (one vial) instilled into the bladder (retain for 2 hours) qw during 3 consecutive weeks at months 3, 6, 12 after initiation of treatment. Beyond one year, maintenance therapy should be evaluated every 6 months until 36 months after initiation of treatment.
Contraindication:
Immunosuppressed patients (eg, HIV infection, leukemia, lymphoma, chemo-therapy, immunosuppressive therapy); active tuberculosis; concurrent febrile illness, urinary tract infection, or gross hematuria; recent biopsy or transurethral resection (TUR) (TheraCys: <14 days; TICE BCG: <7 to 14 days), traumatic catheterization.
Precaution:
Do not administer IV, SubQ,IM, or intradermally.
Drug contains live attenuated mycobacteria; prepare, handle, and dispose as biohazardous material.
Adverse effect:
Dysuria, irritable bladder, urinary frequency,hematuria, cystitis ,urinary tract infection, malaise, chills.